The global 3D cell culture market size was valued at USD 1.5 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 10.7% during the forecast period. As 3D cultures can closely mimic a typical morphology and microarchitecture of organs, they are widely used in studies that require in vivo model systems to analyze the effects of a foreign drug over body tissues and organs. Moreover, biomimetic tissue constructs used to generate 3D organotypic structures drove a large number of research entities to adopt 3-dimensional cell culture techniques. In addition, the usage of 3D tissue-engineered models for Covid-19, cancer, and other clinical disorders has emerged as an alternative approach to traditional techniques. This also shows great potential in providing a relatively simple and inexpensive in vitro tumor-host environment compared to 2D techniques.
The high utility of 3-dimensional models for research about Covid-19 and respiratory diseases is expected to offer significant growth opportunities to the market. Airway and air-liquid interface organoids have been used as tools for the development and discovery of antiviral drugs, and as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2. Scaffold-based and scaffold-free techniques facilitate the bio-fabrication of realistic models that can be used for the development of novel therapeutics and vaccines against Covid-19.
Several other major factors driving the market growth include the launch of new products and wide applications of 3D protocols in biological research. For instance, in December 2020, eNUVIO Inc., a Canada-based biotechnology company, launched EB-Plate, a completely reusable microplate for 3D cell culture. This is expected to reduce the wastage of single-use plastics, increase the utility of 3-dimensional microplates, and propel zero-waste movement in laboratories.
Similarly, standard 2D analysis methods can easily be applied to RAFT 3D cultures manufactured by Lonza. Since these novel technologies do not require many changes to the existing 2D culture methods, they are adopted by many laboratories across the globe. In addition, Lonza has also developed 3D cell culture models to enhance research in areas of hepatic signaling pathways and drug-induced liver injury to improve in vitro hepatotoxicity testing.
Scaffold-based technology accounted for the largest revenue share of over 68.96% in 2020. The use of hydrogels as scaffolds in 3-dimensional cell culture-based research enables the incorporation of sophisticated biochemical and mechanical signs as a mirror of the native extracellular matrix. Moreover, the launch of novel products and the increasing need for advancements in hydrogels for providing robust platforms for studying human and cellular physiology is expected to boost the market growth in the coming years.
In January 2021, researchers from the Southern University of Science and Technology, China developed a method for 3D printing of highly stretchable hydrogels. This helps overcome the limitations associated with the performance and functionality of hydrogel-polymer-based scaffolds. In January 2021, Adocia, a Paris-based biopharmaceutical company, developed a hydrogel scaffold that can be used for cell therapy of Type 1 diabetes.
The growing awareness, as well as popularity, of nanotechnology in biomedical research, is anticipated to create potential growth prospects for nanofiber-based scaffolds, thereby augmenting sales and demand for the scaffold-based technology. Magnetic levitational assembly of 3D tissue constructs is an emerging and fast-growing label & scaffold-free approach for tissue engineering. This is expected to drive the scaffold-free segment with the fastest CAGR over the forecast period.
The cancer segment dominated the market with the largest revenue share of 24.56% in 2020. The use of spheroids as model systems during the development of anticancer therapies drives R&D in this segment. Moreover, the use of 3-dimensional cellular models for the study of cancer biology in preclinical testing and screening is expected to increase revenue generation in this segment.
A January 2021 research study reported the development of polysaccharide hydrogel-based 3D printed tumor models, which can be used for high throughput screening of anti-cancer drugs. Under this study, the researchers aimed at developing hydrogel, which efficiently imitates tumor microenvironment, shows appropriate biocompatibility, rheological characteristics, and printability. Such developments lead to increased use of scaffold-based techniques for cancer.
The stem cell research segment is expected to register the fastest CAGR from 2021 to 2028. A rise in applications of 3D cell culture platforms for regenerative medicine is anticipated to propel the segment growth. In January 2020, Histogen, Inc.—a company engaged in the development of regenerative medicine—entered into a merger with Conatus Pharmaceuticals, Inc. The latter exhibits a robust pipeline of unique clinical candidates, inclusive of an extracellular matrix scaffold targeted toward the treatment of conditions associated with articular cartilage.
The biotechnology and pharmaceutical industries segment generated the largest revenue share of over 46% in 2020. 3D cell cultures have advantages in terms of optimal oxygen and nutrient gradients, non-uniform exposure of cells within a spheroid to a drug, and realistic cell-to-cell interactions in comparison to 2D cell culture to study drug candidates. These factors make 3D cell cultures better suited for drug discovery and development, thereby driving the demand.
Factors, such as the urgent need for more rapid and accurate diagnostic services and the advantages of 3D models over 2D models in providing detailed physiological information, boost the hospitals and diagnostic centers segment growth. In addition, the presence of diagnostic centers, such as Kiyatec that are actively involved in providing 3D models for advanced research, is expected to boost the segment growth in the coming years.
Academic institutes and industrial laboratories are also expected to contribute to the increasing share of this market. Workshops and training programs on 3D cell culture system provided by institutes are anticipated to drive the demand for 3D cell culture products & systems over the forecast period.
North America led the global market in 2020 and accounted for the highest revenue share of over 43%. The region will retain its leading position throughout the forecast period on account of the availability of private and government funding for the development of advanced 3D cell culture models, high healthcare spending, and the presence of a large number of universities and research organizations investigating various stem cell-based approaches. In December 2020, researchers from Mayo Clinic and Terasaki Institute, U.S., developed visible hydrogels that can be used for the monitoring and control of hemorrhage.
The “2020: A New Vision” initiative by the U.S. Department of Health and Human Services recognizes regenerative medicine at the forefront of healthcare. The transformative impact of the use of regenerative medicine at clinical stages is of utmost importance in translational progress and technological innovation. However, Asia Pacific is estimated to be the fastest-growing regional market from 2021 to 2028 owing to increasing investments by various international companies in the emerging economies of this region.
Major market players are focusing on novel product launches and collaborations with other players to enhance the market presence. For instance, In June 2020, Corning, Inc. introduced the Corning X-SERIES cell processing platform for cell and gene therapy applications. This platform delivers sterile, fast, efficient, and automated processing. This product has been manufactured by ThermoGenesis Holdings, Inc. In the same month, the company also launched Corning Matrigel matrix-3D plates for a more convenient and consistent, ready-to-use cell culture option to support organoid and spheroid culture models. Some prominent players in the global 3D cell culture market include:
Merck KGaA
Thermo Fisher Scientific, Inc.
PromoCell GmbH
Greiner Bio One International GmbH
Corning, Inc.
3D Biomatrix
Lonza
Avantor Performance Materials, LLC
Tecan Trading AG
3D Biotek LLC
Global Cell Solutions, Inc.
InSphero
Report Attribute |
Details |
Market size value in 2021 |
USD 1.74 billion |
Revenue forecast in 2028 |
USD 3.48 billion |
Growth rate |
CAGR of 10.7% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2016 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Technology, application, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K.; Japan; China; Brazil; South Africa |
Key companies profiled |
Merck KGaA; Thermo Fisher Scientific, Inc.; PromoCell GmbH; Greiner Bio-One International GmbH; Corning, Inc.; 3D Biomatrix; Lonza; Avantor Performance Materials, LLC; Tecan Trading AG; 3D Biotek LLC; Global Cell Solutions, Inc.; InSphero |
Customization scope |
Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the global 3D cell culture market report on the basis of technology, application, end-use, and region:
Technology Outlook (Revenue, USD Million, 2016 - 2028)
Scaffold-based
Hydrogels
Polymeric Scaffolds
Micro-patterned Surface Microplates
Nanofiber-based Scaffolds
Scaffold-free
Hanging Drop Microplates
Microfluidic 3D Cell Culture
Spheroid Microplates with ULA coating
Magnetic Levitation & 3D Bioprinting
Bioreactors
Application Outlook (Revenue, USD Million, 2016 - 2028)
Cancer
Tissue Engineering & Immunohistochemistry
Drug Development
Stem Cell Research
Others
End-use Outlook (Revenue, USD Million, 2016 - 2028)
Biotechnology and Pharmaceutical Industries
Research Laboratories and Institutes
Hospitals and Diagnostic Centers
Others
Regional Outlook (Revenue, USD Million, 2016 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
Latin America
Brazil
MEA
South Africa
b. Key factors that are driving the 3D cell culture market growth include rising demand for organ transplantation & tissue engineering, technological advancements in scaffold-free technology, and a rise in investments and R&D funding for cell-based research.
b. The global 3D cell culture market size was estimated at USD 1.5 billion in 2020 and is expected to reach USD 1.7 billion in 2021.
b. The global 3D cell culture market is expected to grow at a compound annual growth rate of 10.7% from 2021 to 2028 to reach USD 3.5 billion by 2028.
b. Scaffold-based technology dominated the 3D cell culture market with a share of 69.0% in 2020. This is attributable to the availability of a significant number of products based on the principle of a framework for 3D cell culture.
b. Some key players operating in the 3D cell culture market include Merck KGaA; Thermo Fisher Scientific, Inc.; PromoCell GmbH; Greiner Bio-One International GmbH; Tecan Trading AG; Corning, Inc.; 3D Biomatrix; Lonza; Avantor Performance Materials, LLC; Global Cell Solutions, Inc.; 3D Biotek LLC; and InSphero.
b. The 3D cell culture market is expected to witness numerous growth opportunities during the pandemic, with airway and air-liquid interface organoids being utilized as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2.
b. In January 2021, researchers from the Southern University of Science and Technology, China developed a method for 3D printing highly stretchable hydrogels, to overcome the performance and technology limitations of hydrogel-polymer-based scaffolds.
b. The cancer segment accounted for the highest revenue share of 24.56% in the 3D cell culture market in 2020, in terms of application, with the use of spheroids as model systems for developing anticancer therapies driving R&D of this segment.
b. The biotechnology and pharmaceutical industries segment dominated the 3D cell culture market with more than 46% revenue share in 2020.
b. Asia Pacific is anticipated to show the fastest regional growth in the 3D cell culture market over the forecast period, aided by the increasing investments of major international companies in emerging economies such as India and China.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.